This applies also to well-known erythrocytic vaccine candidates based on ama1, msp1 and eba175, in which variation and selection has been a major hurdle in achieving broad efficacy across malaria endemic populations35, 37, 39. The gene discussed is ATAD1; the disease is malaria.